Sino Biopharmaceutical Limited announced that the National Medical Products Administration (NMPA) of China has approved a new indication for benmelstobart (trade name: Andewei®) injection. The approval is for maintenance therapy in patients with unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed following platinum-based concurrent or sequential chemoradiotherapy and who do not have known EGFR sensitizing mutations or ALK rearrangements. The decision was based on positive results from the R-ALPS phase III clinical study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260216-12025476), on February 15, 2026, and is solely responsible for the information contained therein.